Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Articles > Article · 2017
Authors: B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, Erdem GÖKER, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg
Annals of Oncology, International, WoS, 2017, vol 28, pp 2429-2435